PMID: 24245943
The strategy was then applied to semaglutide, a FDA approved GLP-1 analogue, to generate hybrid 24 and we showed that not only the in vivo activity was preserved, but the stability toward pancreatin was improved opening the way for improvement in oral administration
Bit of Background These new classes of antiobesity medications (ie, the GLP-1 agonists and dual agonists), referred to in this article as weight management medications, arent really new.1-4 The basic science and pharmaceutical research and development to bring these to market began more than two decades ago when two scientists, Matthias Tschop, MD, and Richard DiMarchi, PhD, hypothesized that the actions of various gut hormones may offer safe and unprecedented weight loss
Some 1,257 patients with diabetic neuropathy were randomly assigned to receive, in double-blind fashion, placebo or acetyl-L-Carnitine at a dose of 500 or 1,000 mg 3 times a day for 1 year
C., & Lakshmanan, M